Driving Efficiency: Leveraging Model‐Informed Approaches in 505(b)(2) Regulatory Actions

Abstract

AbstractIntroduced by the Hatch‐Waxman Amendments of 1984, 505(b)(2) applications permit the US Food and Drug Administration to rely, for approval of a new drug application, on information from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. This pathway is designed to circumvent the unnecessary duplication of studies already conducted on a previously approved drug. It can lead to a considerably more efficient and expedited route to approval compared to a traditional development path. Model‐informed drug development refers to the utilization of a diverse array of quantitative models in drug development to streamline the decision‐making process. In this approach, diverse quantitative models that integrate knowledge of physiology, disease processes, and drug pharmacology are employed to address drug development challenges and guide regulatory decisions. Integration of these model‐informed approaches into 505(b)(2) regulatory submissions and decision‐making can further expedite the approval of new drugs. This article discusses some applications of model‐informed approaches that were used to support 505(b)(2) drug development and regulatory actions. Specifically, various quantitative models such as population pharmacokinetic and exposure‐response models have been employed to provide evidence of effectiveness, guide dosing in subgroups such as subjects with hepatic or renal impairment, and inform policies. These case study examples collectively underscore the significance of model‐informed approaches in drug development and regulatory decisions associated with 505(b)(2) submissions.